10/11/2013

AstraZeneca and Johnson & Johnson agreed to jointly promote the latter's prostate cancer drug abiraterone in Japan. The drug, marketed as Zytiga in the U.S. and Europe, is under regulatory review in Japan.

Full Story:
Reuters

Related Summaries